These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36507738)

  • 41. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.
    Bravermanová A; Viktorinová M; Tylš F; Novák T; Androvičová R; Korčák J; Horáček J; Balíková M; Griškova-Bulanova I; Danielová D; Vlček P; Mohr P; Brunovský M; Koudelka V; Páleníček T
    Psychopharmacology (Berl); 2018 Feb; 235(2):491-503. PubMed ID: 29302713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
    Small DS; Payne CD; Kothare P; Yuen E; Natanegara F; Teng Loh M; Jakubowski JA; Richard Lachno D; Li YG; Winters KJ; Farid NA; Ni L; Salazar DE; Tomlin M; Kelly R
    Clin Ther; 2010 Feb; 32(2):365-79. PubMed ID: 20206794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose crossover studies.
    Kim BH; Kim JR; Kim MG; Kim KP; Lee BY; Jang IJ; Shin SG; Yu KS
    Clin Ther; 2010 Jan; 32(1):193-205. PubMed ID: 20171424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
    Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
    J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study.
    Abd-Rahman AN; Marquart L; Gobeau N; Kümmel A; Simpson JA; Chalon S; Möhrle JJ; McCarthy JS
    Clin Pharmacol Ther; 2020 Nov; 108(5):1055-1066. PubMed ID: 32415986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
    Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; Weston N; Malievskaia E; Young AH
    J Psychopharmacol; 2022 Jan; 36(1):114-125. PubMed ID: 35090363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.
    Badri P; Jiang X; Borodovsky A; Najafian N; Kim J; Clausen VA; Goel V; Habtemariam B; Robbie GJ
    Clin Pharmacokinet; 2021 Mar; 60(3):365-378. PubMed ID: 33047216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of pharmacokinetic and pharmacodynamic profiles and tolerability after single (2.5, 5, or 10 mg) and repeated (2.5, 5, or 10 mg bid for 4.5 days) oral administration of ivabradine in healthy male Korean volunteers.
    Choi HY; Noh YH; Cho SH; Ghim JL; Choe S; Kim UJ; Ah Jung J; Bae KS; Lim HS
    Clin Ther; 2013 Jun; 35(6):819-35. PubMed ID: 23755867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
    Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
    J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers.
    Motoki K; Igarashi T; Omura K; Nakatani H; Iwanaga T; Tamai I; Ohashi T
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00533. PubMed ID: 31788318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers.
    Yoon DY; Sunwoo J; Shin N; Kim AR; Kim B; Song GS; Jang IJ; Lee S
    Clin Transl Sci; 2021 May; 14(3):934-941. PubMed ID: 33382926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
    Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of norethisterone in humans.
    Shi YE; He CH; Gu J; Fotherby K
    Contraception; 1987 May; 35(5):465-75. PubMed ID: 3621943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
    Studerus E; Kometer M; Hasler F; Vollenweider FX
    J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects.
    Li N; Du S; Wang Y; Zhu X; Shu S; Men Y; He M; Fang F; Wang Y; Gong Y; Chen J; Gu L; Cheng Y; He Q; Lu H; Niu Y; Xu Y; Feng P
    Eur J Pharm Sci; 2022 Sep; 176():106257. PubMed ID: 35820629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.